Fig. 2From: Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III studyMean (bold red line) and individual changes in systolic and diastolic blood pressure from pre-dose values during IV infusion 1 (Day 2) and IV infusion 3 (Day 3). IV, intravenousBack to article page